Select Clinical Trial
Protocol Number: Amgen 20210096 (FORTITUDE-101)
Protocol Title: A randomized, double-blind, placebo-controlled phase 3 study of Bemarituzumab plus chemotherapy versus placebo plus chemotherapy in subjects with previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b Overexpression
Eligibility: Men and women age 18 and older with unresectable, locally advanced, or metastatic histologically documented gastric or GEJ adenocarcinoma.
Contact Information: (910) 715-2200